Xavier Forns

Hepatology Services Hepatologist

Research group

Viral, genetic and immune-mediated liver diseases Group leader (R4)

xforns@clinic.cat 0000-0002-8188-1764

Featured publications

Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: relevance of non-characterized nodules

Authors: Mariño Z, Darnell A, Lens S, Sapena V, Díaz A, Belmonte E, Perelló C, Calleja JL, Varela M, Rodriguez M, Rodriguez de Lope C, Llerena S, Torras X, Gallego A, Sala M, Morillas RM, Minguez B, Llaneras J, Coll S, Carrion JA, Iñarrairaegui M, Sangro B, Vilana R, Sole M, Ayuso C, Ríos J, Forns X, Bruix J, Reig M .

Reference: Journal Of Hepatology 2019.
Hepatitis C virus early kinetics and resistance-associated substitution dynamics during antiviral therapy with direct-acting antivirals.

Authors: Perpiñán E, Caro-Pérez N, García-González N, Gregori J, González P, Bartres C, Soria ME, Perales C, Lens S, Mariño Z, Londoño MC, Ariza X, Koutsoudakis G, Quer J, González-Candelas F, Forns X, Pérez-Del-Pulgar S .

Reference: Journal Of Viral Hepatitis 2018.
Shorter HBIG administration is not associated to HBV recurrence when receiving combined prophylaxis after liver transplantation.

Authors: Lens S, García-Eliz M, Fernández I, Castells L, Bonacci M, Mas A, Crespo G, Buti M, Prieto M, Forns X .

Reference: Liver International 2018.
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.

Authors: Reau N, Kwo PY, Rhee S, Brown RS, Agarwal K, Angus P, Gane E, Kao JH, Mantry PS, Mutimer D, Reddy KR, Tran TT, Hu YB, Gulati A, Krishnan P, Dumas EO, Porcalla A, Shulman NS, Liu W, Samanta S, Trinh R, Forns X .

Reference: Hepatology 2018.
Sofosbuvir/Velpatasvir for 12 Weeks in Genotype 1-4 HCV-Infected Liver Transplant Recipients.

Authors: Agarwal K, Castells L, Müllhaupt B, Rosenberg WMC, McNabb B, Arterburn S, Camus G, McNally J, Stamm LM, Brainard DM, Mani Subramanian G, Mariño Z, Dufour JF, Forns X .

Reference: Journal Of Hepatology 2018.
Long-Term Outcomes of Patients With HCV-Associated Cryoglobulinemic Vasculitis After Virologic Cure.

Authors: Bonacci M, Lens S, Mariño Z, Londoño MC, Rodriguez-Tajes S, Sánchez-Tapias JM, Ramos-Casals M, Hernández-Rodríguez J, Forns X .

Reference: Gastroenterology 2018.
The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition

Authors: Crespo G; Trota N; Londoño MC; Mauro E; Baliellas C; Castells L; Castellote J; Tort J; Forns X; Navasa M.

Reference: Journal Of Hepatology 2018.
Effects of All-oral Anti-viral Therapy on HVPG and Systemic Hemodynamics in Patients with Hepatitis C Virus-associated Cirrhosis.

Authors: Lens S, Alvarado-Tapias E, Mariño Z, Londoño MC, LLop E, Martinez J, Fortea JI, Ibañez L, Ariza X, Baiges A, Gallego A, Bañares R, Puente A, Albillos A, Calleja JL, Torras X, Hernández-Gea V, Bosch J, Villanueva C, Forns X, García-Pagán JC .

Reference: Gastroenterology 2017.
Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial.

Authors: Forns X, Lee SS, Valdes J, Lens S, Ghalib R, Aguilar H, Felizarta F, Hassanein T, Hinrichsen H, Rincon D, Morillas R, Zeuzem S, Horsmans Y, Nelson DR, Yu Y, Krishnan P, Lin CW, Kort JJ, Mensa FJ .

Reference: Lancet Infectious Diseases 2017.
EASL Recommendations on Treatment of Hepatitis C 2016

Authors: ;European Ass Study Liver.

Reference: Journal Of Hepatology 2017.

Featured Projects

Estudio de la disfunción de la respuesta inmune adaptativa periférica e intrahepática en las diferentes fases de la hepatitis crónica por el virus de la hepatitis B

Principal investigator: Xavier Forns Bernhardt

Funder: Instituto de Salud Carlos III

Code: PI18/00079

Duration: 01/01/2019 - 01/01/2022
Evaluación prospectiva de un modelo externalizado de consulta especializada con intervención educacional para reducir la reinfección por el virus de la hepatitis C en un centro de reducción de daños

Principal investigator: Xavier Forns Bernhardt

Funder: Ministerio de Sanidad

Code: 2020I018

Duration: 01/01/2021 - 31/12/2022
TherVacB: A therapeutic vaccine to cure hepatitis B

Principal investigator: Xavier Forns Bernhardt

Funder: European Commission

Code: 848223

Duration: 01/01/2020 - 31/12/2024

Web: https://www.thervacb.eu/
Defining the best strategy for global HCV screening, linkage-to-care, education and prevention in PWID population and validation of a new diagnostic dried blood spot test

Principal investigator: Sabela Lens García

Funder: GILEAD SCIENCES INC

Code: IN-ES-987-5349

Duration: 02/05/2018 - 31/03/2022

Xavier Forns

Research group

Featured publications

Featured Projects

Estudio de la disfunción de la respuesta inmune adaptativa periférica e intrahepática en las diferentes fases de la hepatitis crónica por el virus de la hepatitis B

Evaluación prospectiva de un modelo externalizado de consulta especializada con intervención educacional para reducir la reinfección por el virus de la hepatitis C en un centro de reducción de daños

TherVacB: A therapeutic vaccine to cure hepatitis B

Defining the best strategy for global HCV screening, linkage-to-care, education and prevention in PWID population and validation of a new diagnostic dried blood spot test

Subscribe to the Newsletter of Clínic